Monday, May 28, 2012

MarketAark : CORD BLOOD BANKING - Comprehensive Industry Database (2012)

As the global leader in stem cell industry data, one of the questions that we get asked every day is, "How many cord blood banks are active in the world, right now?" If you run a cord blood bank, you must have wondered that question yourself at one point or another. Did you know that as of 2012, the answer is 510 total from 97 different countries? 

While you may know that the cord blood banking industry is expanding with double-digit growth, you may not have known that exact number above - but a lack of awareness could be harming your business. Let knowledge be your power, instead of your limitation. Find out more by accessing a complete list of those cord blood banks worldwide. Become aware of the companies and organizations operating in your industry and take advantage of the opportunities for collaboration and profit. 

The comprehensive Cord Blood Database includes: 

•Global List of Cord Blood Banks: The only comprehensive list available that contains all active cord blood banks worldwide (510 total)

•Breakdown by Country: A country-by-country breakdown of cord blood banks worldwide (97 different countries)

•Individual Company Contacts: 4,454 Contacts for individuals employed at cord blood banks worldwide (Includes company name, country, email address, first name, last name, title, phone number, and website, as available)

•Other Industry Contacts: 2,461 contacts for individuals working in the Cord Blood Industry at large, including contacts from the following categories: 

- Academia
- Biotech/Pharma Company
- Blood Center
- Bone Marrow Program
- Cord Blood Bank
- Government
- Hospital
- Medical Center
- Research Center

The database contains nearly 7,000 cord blood industry contacts from across the globe.

It reveals the Top 15 Countries for Cord Blood Banking Worldwide, as ranked by number of cord blood banking branches active within the country, to be: 

1. USA
2. Italy
3. Spain
4. Germany
5. United Kingdom
6. India
7. Canada
8. Israel
9. Brazil
10. Australia
11. Belgium
12. Poland
13. Chile
14. Cyprus
15. China
For more information, please visit:
http://www.aarkstore.com/reports/CORD-BLOOD-BANKING-Comprehensive-Industry-Database-2012--197551.html
Or email us at press@aarkstore.com or call +919272852585
More Reports
Stem Cell Research Products - Opportunities, Tools, and Technologies
 Mesenchymal Stem Cells, Advances & Applications
 Capitalizing on Opportunities in Cord Blood Industry Growth
 Strategic Development of Neuronal Stem & Progenitor Cell Products
 Opportunities in Human Embryonic Stem Cell (hESC) Products
 CORD BLOOD BANKING - Comprehensive Industry Database (2012)
 Profitable Opportunities in Pharmacodynamic Assay Development
Aarkstore Enterprise
Tel : +912227453309
Mobile No: +919272852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://blogs.aarkstore.com/
Follow us on twitter: http://twitter.com/aarkstoredotcom
Posted by at No comments:
Labels: , , ,

MarketAark : Opportunities in Human Embryonic Stem Cell (hESC) Products

Overview:  Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reach 4-5 days post fertilization. They are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body, providing tremendous therapeutic potential.
Human ESCs were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of primate embryonic stem cells occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow human embryonic stem cells derived from human blastocysts.
As a result of these significant accomplishments at the University of Wisconsin, the Wisconsin Alumni Research Foundation (WARF) filed a series of landmark patents that have affected the intellectual property landscape ever since. These “composition of matter” patents concerning primate embryonic stem cells are controversial because they are so broad that they cover all human embryonic stem cell lines in the United States, not just the specific stem cell lines developed by James Thompson.
Since this time, WARF has been the major “gatekeeper” determining which research product companies have been allowed to conduct research and create commercial products using hESCs. WARF has also been in control of what pharmaceutical companies have been able to develop hESC therapies. Since obtaining its landmark patents in 1998, WARF has only entered into licensing agreements with 27 commercial partners for its intellectual portfolio related to isolating and differentiating hESCs, of which only 15 have been disclosed. 300 academic laboratories have also received agreements for using the technology without charge.
The low number of licensing agreements suggests that many companies find WARF’s licensing fees to be unwieldy, which isn’t surprising given that disclosed fees have ranged from $75,000 to more than $250,000, plus annual payments and royalties. While Invitrogen, Becton Dickinson and Chemicon have disclosed licensing agreements with WARF, many research products companies have to explore less costly alternatives – such as circumventing the claims, conducting research off-shore, potential use of abnormal karyotypes, developing embryonic stem cell products for other species, and pursuing strategic collaborations.
This market report explores the complex IP landscape affecting development of human embryonic stem cell products, providing clear guidance for companies that want enter the product area.
In addition, it contains:
  • Discussion of key advances in hESC research
     
  • A breakdown of hESC research applications, including shared priorities and priorities by segment 
     
  • Historical and future growth projections for the hESC market
     
  • U.S. and international hESC patent analysis
     
  • Competitive analysis of providers of hESC research tools
     
  • Overview of specialty pharma companies developing hESC therapies
     
  • Overview of toxicology testing legislation impacting use of hESC in toxicology applications
     
  • A breakdown of hESC research product categories
     
  • Suggestions for novel NSC research products, including cells, kits, assays, media and reagents
     
  • Guidance for companies that wish to offer hESCs products
     
  • And more…
For more information, please visit:
http://www.aarkstore.com/reports/Opportunities-in-Human-Embryonic-Stem-Cell-hESC-Products-32477.html
Or email us at press@aarkstore.com or call +919272852585
More Reports
Stem Cell Research Products - Opportunities, Tools, and Technologies
 Mesenchymal Stem Cells, Advances & Applications
 Capitalizing on Opportunities in Cord Blood Industry Growth
 Strategic Development of Neuronal Stem & Progenitor Cell Products
 Opportunities in Human Embryonic Stem Cell (hESC) Products
 CORD BLOOD BANKING - Comprehensive Industry Database (2012)
 Profitable Opportunities in Pharmacodynamic Assay Development
Aarkstore Enterprise
Tel : +912227453309
Mobile No: +919272852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://blogs.aarkstore.com/
Follow us on twitter: http://twitter.com/aarkstoredotcom
Posted by at No comments:
Labels: , , , , ,

Sunday, May 27, 2012

MarketAark : Strategic Development of Neuronal Stem & Progenitor Cell Products

Overview: 
Neurogenesis is the process by which neurons are created. This process is most active during pre-natal development when neurogenesis is responsible for populating the growing brain. Neural stem cells (NSCs) are the self-renewing, multipotent cells that differentiate into the main phenotypes of the nervous system. These cell types include neurons, astrocytes, and oligodendrocytes. Neural progenitor cells (NPCs) are the progeny of stem cell division that normally undergo a limited number of replication cycles in vivo. 
 
The terms neuronal and neural also need to be defined. Technically speaking, “neuronal” means “pertaining to neurons”, and “neural” means “pertaining to nerves, which are the cordlike bundles of fibers made up of neurons.” Since both terms ultimately are descriptive of neurons, the scientific community uses the terms "neuronal" and "neural" interchangeably. The complexity of this issue is explored from a marketing perspective within this report. 
 
In 1992, Reynolds and Weiss were the first to isolate neural stem cells from the striatal tissue of adult mice brain tissue, including the subventricular zone, which is a neurogenic area. Since then, neural progenitor and stem cells have been isolated from various areas of the adult brain, including non-neurogenic areas like the spinal cord, and from other species, including humans. During the development of the nervous system, neural progenitor cells can either stay in the pool of proliferating undifferentiated cells or exit the cell cycle and differentiate. 
 
Over the past few years, neuronal stem and progenitor cells have become of profound interest to the research community due to their potential to be used in drug discovery and delivery applications, as well as for tools of neural toxicology assessment. NSC transplantation also represents a ground-breaking approach for treating a range of chronic neurological diseases and acute CNS injuries, including Parkinson’s, Alzheimer’s and spinal cord injury, among other conditions. 
 
This market report focuses on recent advances in NSC research applications, explores research priorities by market segment, highlights individual labs and end-users of neuronal stem cell research products, explores the competitive environment for NSC research products, and provides 5-year growth and trend analysis. It provides detailed guidance for companies that wish to offer strategically positioned NSC research products, including cells, kits, assays, and related media and reagents.
This market report includes:
  • Recent advances in NSC research applications
  • Research priorities by market segment
  • Competitive analysis of NSC research supply companies
  • Segmentation of existing NSC products
  • Individual labs and end-users of NSC research products
  • Patent analysis
  • Overview of specialty pharmaceutical companies developing NSC therapies
  • 5-year market growth projections and trend analysis
  • Detailed guidance for companies that wish to offer strategically positioned NSC research products, including cells, kits, assays, media and reagents
  • And much more
For more information, please visit:
http://www.aarkstore.com/reports/Strategic-Development-of-Neuronal-Stem-Progenitor-Cell-Products-32473.html
Or email us at press@aarkstore.com or call +919272852585
More Reports
Stem Cell Research Products - Opportunities, Tools, and Technologies
 Mesenchymal Stem Cells, Advances & Applications
 Capitalizing on Opportunities in Cord Blood Industry Growth
 Strategic Development of Neuronal Stem & Progenitor Cell Products
 Opportunities in Human Embryonic Stem Cell (hESC) Products
 CORD BLOOD BANKING - Comprehensive Industry Database (2012)
 Profitable Opportunities in Pharmacodynamic Assay Development
Aarkstore Enterprise
Tel : +912227453309
Mobile No: +919272852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://blogs.aarkstore.com/
Follow us on twitter: http://twitter.com/aarkstoredotcom
Posted by at No comments:
Labels: , , , , ,

MarketAark : Capitalizing on Opportunities in Cord Blood Industry Growth

Overview: 
Over the past 12 months, the cord blood banking industry has expanded through double digit growth, due to new entrants in the cord blood banking industry, as well as revenue growth at existing operations. To guide industry competitors, this report considers the questions:
·         What factors are causing a substantial number of new cord blood banks to open up business?
·         What will be the effect of these new entrants to the cord blood banking industry for existing competitors?
·         How can existing competitors maintain a position of dominance in the industry among this trend?
Deeper analysis also reveals that existing cord blood banks follow a bi-modal distribution, either experiencing flat-line growth (less than 3% per annum) or substantively building revenue (25% or more per annum).
While a similar bimodal distribution existed in the prior 12 month period (trailing 12 to 24 months), the peaks have continued to separate over the past 12 months, with the average flat-growth company staying stagnant and the average revenue growth company increasing its per annum growth rate from 17% per year to 25% per year. This trend indicates an increasing shift in dominance toward fast-growth companies, which begs the questions:
·         What are the differences among the cord blood banks that are experiencing flat-line growth, versus those that have substantively building revenue?
·         Why are the fast-growth companies continuing to increase their dominance relative to the flat growth companies?
Over the past 12 months, there has also been particularly fast industry growth within specific regions of the world. This report considers the models and tactics used within those regions in order to identify strategies that businesses in other regions should consider leveraging as approaches for growth.
In sum, this expanded and updated version includes:
·         Supplemental analysis of factors that have produced double-digit industry growth over the trailing 12 months
·         Guidance on how to break through flat-line growth to become a fast-growing competitor within the cord blood industry
·         Novel global tactics for growth that can be leveraged without respect to country
·         Results from a detailed survey of expectant parents to provide insight into the perspectives and decisions of prospective clients
For more information, please visit:
Or email us at press@aarkstore.com or call +919272852585
More Reports
Aarkstore Enterprise
Tel : +912227453309
Mobile No: +919272852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://blogs.aarkstore.com/
Follow us on twitter: http://twitter.com/aarkstoredotcom
Posted by at No comments:
Labels: , , , , , ,

MarketAark : Capitalizing on Opportunities in Cord Blood Industry Growth

Overview: 
Over the past 12 months, the cord blood banking industry has expanded through double digit growth, due to new entrants in the cord blood banking industry, as well as revenue growth at existing operations. To guide industry competitors, this report considers the questions:
·         What factors are causing a substantial number of new cord blood banks to open up business?
·         What will be the effect of these new entrants to the cord blood banking industry for existing competitors?
·         How can existing competitors maintain a position of dominance in the industry among this trend?
Deeper analysis also reveals that existing cord blood banks follow a bi-modal distribution, either experiencing flat-line growth (less than 3% per annum) or substantively building revenue (25% or more per annum).
While a similar bimodal distribution existed in the prior 12 month period (trailing 12 to 24 months), the peaks have continued to separate over the past 12 months, with the average flat-growth company staying stagnant and the average revenue growth company increasing its per annum growth rate from 17% per year to 25% per year. This trend indicates an increasing shift in dominance toward fast-growth companies, which begs the questions:
·         What are the differences among the cord blood banks that are experiencing flat-line growth, versus those that have substantively building revenue?
·         Why are the fast-growth companies continuing to increase their dominance relative to the flat growth companies?
Over the past 12 months, there has also been particularly fast industry growth within specific regions of the world. This report considers the models and tactics used within those regions in order to identify strategies that businesses in other regions should consider leveraging as approaches for growth.
In sum, this expanded and updated version includes:
·         Supplemental analysis of factors that have produced double-digit industry growth over the trailing 12 months
·         Guidance on how to break through flat-line growth to become a fast-growing competitor within the cord blood industry
·         Novel global tactics for growth that can be leveraged without respect to country
·         Results from a detailed survey of expectant parents to provide insight into the perspectives and decisions of prospective clients
For more information, please visit:
Or email us at press@aarkstore.com or call +919272852585
More Reports
Aarkstore Enterprise
Tel : +912227453309
Mobile No: +919272852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://blogs.aarkstore.com/
Follow us on twitter: http://twitter.com/aarkstoredotcom
Posted by at No comments:
Labels: , , , , , ,

MarketAark : Mesenchymal Stem Cells, Advances & Applications

This is an expanded and updated report that includes: 
  - 55 New Pages of Material
  - Charts, Timelines, Metrics and Financials Updated for 2011
  - 5-Year Projection Data Spanning 2011-2016
  - Expanded Competitive Environment Analysis
  - Detailed Characterization of the Market, Emphasizing Statistical Trending
  - Exploration of Recent Product Evolution and Projected Directions for Development
  - Overview of Therapeutic Progress and Insight into Future Applications
  - Detailed Evaluation of Profit Opportunities
  - New Section on End-User Interests, Needs, Technical Preferences (Scientist Panel)
Overview :   
Analysis of global grant activity, scientific publication rates, and patent applications reveal that research activity involving mesenchymal stem cells increased 58% year-over-year from 2008 to 2009, and 112% from 2009 to 2010. Of most interest is that this rate is accelerating in 2011, making mesenchymal stem cells the fastest growing area of stem cell research.
Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal cells. MSCs are of intense therapeutic interest because they represent a population of cells with the potential to treat a wide range of acute and degenerative diseases. MSCs are advantageous over other stem cells types for several reasons. First, they avoid the ethical issues that surround embryonic stem cell research. Second, repeated studies have found that human MSCs are immuno-privileged, and therefore, represent an advantageous cell type for allogenic transplantation, reducing the risks of rejection and complications of transplantation. Recently, there have also been significant advances in the use of autologous MSCs to regenerate human tissues, including cartilage and meniscus, tendons, and bone fractures.
This market research report focuses on recent advances in MSC research applications, explores research priorities by market segment, highlights individual labs and end-users of MSC research products, explores the competitive environment for MSC research products, and provides 5-year growth and trend analysis. The report advantageously positions companies that wish to offer competitive stem cells products to this rapidly growing, well-funded research community.
For more information, please visit:
Or email us at press@aarkstore.com or call +919272852585
More Reports
Aarkstore Enterprise
Tel : +912227453309
Mobile No: +919272852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://blogs.aarkstore.com/
Follow us on twitter: http://twitter.com/aarkstoredotcom
Posted by at No comments:
Labels: , , , , ,
Subscribe to: Posts (Atom)